The cannabinoid system and microglia in health and disease

Samuel S Duffy1, Jessica P Hayes1, Nathan T Fiore1

  • 1Translational Neuroscience Facility, School of Medical Sciences, University of New South Wales, UNSW Sydney, NSW, 2052, Australia.

Neuropharmacology
|April 12, 2021
PubMed

Insights

Microglia, the brain's immune cells, utilize the cannabinoid system to protect the central nervous system (CNS). Activating this system may offer therapeutic benefits for various neurological and psychiatric disorders.

Area of Science:

  • Neuroimmunology
  • Neuropharmacology
  • Cellular Neuroscience

Background:

  • Microglia are the primary immune cells of the central nervous system (CNS), crucial for development, immune surveillance, and neuronal health.
  • In neurological diseases, microglia transition from a homeostatic state to an activated phenotype, such as disease-associated microglia (DAM).
  • Microglia synthesize endocannabinoids and express cannabinoid receptors (CB1 and CB2), which are modulated during activation.

Purpose of the Study:

  • To review the role of the microglial cannabinoid system in various CNS disorders.
  • To explore the therapeutic potential of cannabinoids in modulating microglial activity.
  • To highlight the immunomodulatory effects of cannabinoids on microglia.

Main Methods:

  • Literature review and synthesis of existing research on microglia and the endocannabinoid system.
  • Analysis of microglial transcriptomic signatures in health and disease.
  • Examination of cannabinoid receptor expression and endocannabinoid synthesis in activated microglia.

Main Results:

  • Activated microglia upregulate endocannabinoid synthesis and CB2 receptor expression, promoting a neuroprotective phenotype.
  • The microglial cannabinoid system is implicated in multiple sclerosis, Alzheimer's disease, Parkinson's disease, ALS, chronic pain, depression, anxiety, and schizophrenia.
  • Cannabinoid receptor 2 (CB2) activation enhances neuroprotective factor production and reduces pro-inflammatory factors in microglia.

Conclusions:

  • The microglial cannabinoid system represents a promising therapeutic target for a range of neurological and psychiatric conditions.
  • Modulating microglial activity via cannabinoids could offer novel treatment strategies for CNS disorders.
  • Further research is needed to elucidate the specific microglia-dependent immunomodulatory effects of cannabinoids.